Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Total Non-Current Liabilities (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $152.2 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 40.86% to $152.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $152.2 million through Dec 2025, up 40.86% year-over-year, with the annual reading at $152.2 million for FY2025, 40.86% up from the prior year.
  • Total Non-Current Liabilities hit $152.2 million in Q4 2025 for Vanda Pharmaceuticals, up from $124.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $152.2 million in Q4 2025 to a low of $72.9 million in Q1 2021.
  • Historically, Total Non-Current Liabilities has averaged $101.3 million across 5 years, with a median of $99.8 million in 2024.
  • Biggest five-year swings in Total Non-Current Liabilities: dropped 9.08% in 2023 and later surged 40.86% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $84.5 million in 2021, then rose by 18.67% to $100.2 million in 2022, then decreased by 5.53% to $94.7 million in 2023, then rose by 14.12% to $108.1 million in 2024, then surged by 40.86% to $152.2 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for VNDA at $152.2 million in Q4 2025, $124.1 million in Q3 2025, and $128.4 million in Q2 2025.